Publication | Closed Access

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

MedicinePharmacologyDays On/7 DaysNovel Raf KinaseRefractory Solid TumorsCancer TreatmentAnti-cancer AgentOncologyRadiation Oncology